Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.

Current issues in molecular biology - 5 Aug 2021

Yun Jina, Ji Young Sok, Jang Geum Ha, Lim Sung Hee, Kim Se Hyung, Kim Chan Kyu, Bae Sang Byung, Won Jong Ho, Park Seong Kyu

Abstract excerpt

Tet methylcytosine dioxygenase 2 (TET2) is one of the most frequently mutated genes in myelodysplastic syndrome (MDS). TET2 is known to involve a demethylation process, and the loss of TET2 is thought to cause DNA hypermethylation. Loss of TET2 function is known to be caused by genetic mutations and miRNA, such as miR-22. We analyzed 41 MDS patients receiving hypomethylating therapy (HMT) to assess whether TET2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Dioxygenases

Share to MicroRNAs

Share to Myelodysplastic Syndromes

Share to Proto-Oncogene Proteins

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34449560
DOI: 10.3390/cimb43020065
PMCID: PMC8929064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.PMID 34449560Read ↗

Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.Semantic proximity Read ↗

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.Semantic proximity Read ↗

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.Semantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

[Molecular and clinical characteristics and prognosis of myelodysplastic neoplasms with biallelic TET2 inactivation].Semantic proximity Read ↗

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.Semantic proximity Read ↗

Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.Semantic proximity Read ↗

TET2 mutations in myelodysplasia and myeloid malignancies.Semantic proximity Read ↗

Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.Semantic proximity Read ↗

Acquired mutations in TET2 are common in myelodysplastic syndromes.Semantic proximity Read ↗

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.Semantic proximity Read ↗

Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.